A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count

Article Medicine, Research & Experimental

Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing

Elsa Noaks et al.

Summary: The removal of monocytes from leukapheresis has been shown to enhance the activation level and transduction efficiency of CAR T cells, leading to improved production consistency and increased CAR expression levels.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2021)

Add to Collection

Article Medicine, General & Internal

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Bijal D. Shah et al.

Summary: KTE-X19 demonstrated a high rate of complete remission or complete remission with incomplete haematological recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Median overall survival was not reached in responding patients, and the therapy showed a manageable safety profile. These findings suggest that KTE-X19 has the potential to provide long-term clinical benefit to these patients.

LANCET (2021)

Add to Collection

Article Medicine, Research & Experimental

Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives

Keywan Mortezaee

Summary: Myeloid-derived suppressor cells (MDSCs) are a group of immature immune cells that significantly increase in cancer patients, releasing factors that impact tumor-related events such as metastasis and immune evasion, and can serve as an indicator of tumor prognosis. They can be targeted in combination with current immunotherapies to enhance the immune system's response against tumors.

LIFE SCIENCES (2021)

Add to Collection

Review Pharmacology & Pharmacy

Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope

Alejandrina Hernandez-Lopez et al.

Summary: Cancer is a leading cause of death worldwide, and immunotherapy, particularly CAR-T cell therapy, has shown promise in treating patients who have not responded to traditional treatments. However, there are still challenges to overcome in making this technology a first-line clinical treatment.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Review Oncology

Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

Mohamed Abou-el-Enein et al.

Summary: This review discusses the current status of commercially available CAR T cell therapies for hematologic malignancies and the shift towards Good Manufacturing Practice-compliant closed and automated systems in the industry. It also highlights the emerging technologic advances in CART cell manufacturing and the challenges in scaling production for clinical use. The review emphasizes the significance of closed and automated production platforms to meet the increasing demand for CAR T cell cancer therapy.

BLOOD CANCER DISCOVERY (2021)

Add to Collection

Review Health Care Sciences & Services

Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997-2020)

Nikola A. Ivica et al.

Summary: CAR-T/TCR-T cellular immunotherapies have shown remarkable success in treating refractory B-cell malignancies. The increase in clinical trials is driven by the development of different CAR-T products, with China and the US being major innovators in the field. This industry exhibits a robust response to competitor products, with the term "bioparallels" coined to describe similar therapeutic approaches.

HEALTHCARE (2021)

Add to Collection

Review Hematology

Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration

Maurice Alexander et al.

Summary: CAR T therapy has become an integral part of treatment for acute leukemia, lymphoma, and multiple myeloma, with a growing number of clinical trials in both hematologic and solid tumor malignancies. Clinical toxicities include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Despite the expected shift towards outpatient administration and monitoring, reimbursement for inpatient treatment poses a threat to the sustainability of inpatient CAR T therapy.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Review Cell & Tissue Engineering